Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by Dachs1on Aug 19, 2017 1:51am

134 Views

Post# 26599077

RE:SBM needs the upfront payment

I wrote that I do not much care about the value of the upfront and milestone payments. Of course, the upfront payment should be so high to finance the operating business until royalty fee comes in.
For this, Sirona does not need 90 MUSD, 20 MUSD would be also enough.

The upside here is a global roll-out of 1067 in a 23 billion USD market.

Bullboard Posts

Who, why, and what of the great "Crypto Surge"